111(US:YI)2022-08-25 10:57Financial Performance - Revenue reached RMB 3037145000 despite difficult circumstances[12, 44] - Gross profit significantly increased to RMB 192 million, a 43% year-over-year increase[12] - B2B segment revenue increased by 13% year-over-year to RMB 2935000000[16, 31] - B2B segment gross profit increased by 55% year-over-year to RMB 169 million[15, 16] - B2C segment revenue decreased by 20% year-over-year to RMB 103 million[31] - Non-GAAP operating loss as a percentage of net revenue decreased by 320 basis points year-over-year to 17%[17] Operational Efficiency - G&A expense as a percentage of net revenue decreased by 25% year-over-year[17] - Operating expense as a percentage of net revenue decreased from 107% in 2021 Q2 to 89% in 2022 Q2 including share-based compensation expenses[35] New Initiatives - 1 Health program connects digitally with over 67 million patients, with a 48% quarter-over-quarter increase in patients[18] - High Margin Product Program saw a 232% year-over-year increase in GMV[20] - Cloud Promotion Platform covered over 7000 pharmacies and 9000 pharmacy managers/pharmacists/salespersons[24]